Introduction
Insulin-like growth factor-I (IGF-I) and its receptor (IGF-IR) are key proteins involved in proliferation, differentiation and malignant transformation and are expressed in numerous ocular cell types, including retinal endothelial cells (RECs), lens epithelial cells, 1 retinal pigment epithelial cells, 2 cone photoreceptor cells 3 and Mü ller cells. 4 IGF-I and its receptor are required for normal ocular development including the vasculature. IGF-I has been shown to play a key role in retinopathy of prematurity (ROP). 5 Hellstrom et al. 6 showed that lack of IGF-I in knockout mice prevents normal retinal vascular growth, despite the presence of vascular endothelial growth factor (VEGF). Inadequate levels of IGF-I in vitro result in loss of VEGF-induced activation of protein kinase B (Akt), a kinase critical for endothelial cell survival. 5 These studies emphasize the salient role of IGF-IR in orchestrating the function of other growth factors in the eye.
Hellstrom et al. 6 postulated that if sufficient serum levels of IGF-I are maintained after birth in premature infants, normal vessel development occurs and ROP does not develop. However, when serum IGF-I, which reflects retinal IGF-I, is persistently low, vessels cease to grow, and the maturing avascular retina becomes hypoxic resulting in VEGF accumulation in the vitreous. These authors went on to hypothesize that as IGF-I increases to a critical level, retinal neovascularization is triggered. Their data indicate that serum IGF-I levels in premature infants can predict which infants will develop ROP.
The role of IGF-I has not been well established in normal retinal vessel development in humans. Retinal vessel morphology was evaluated in patients with genetic defects of the IGF-I axis. Patients with low serum levels of IGF-I during and after normal retinal vessel growth had significantly less retinal vascularization, as evidenced by lower numbers of vascular branching points, compared with the reference group of normal controls. This is the first study to provide genetic evidence for a role of IGF-I system in retinal vascularization in humans. 6 The IGF-I/IGF-IR axis has also been shown to influence the progression of proliferative diabetic retinopathy (PDR). Pivotal studies by Merimee et al. 7 showed the first association of serum IGF-I levels with disease severity. They identified a group of diabetic patients with markedly accelerated neovascularization. These patients had very high serum IGF-I levels, compared to diabetic patients with slower advancing disease. 7 This correlation was corroborated by others. [8] [9] [10] Chantelau et al. 11 found that elevated IGF-I serum levels preceded PDR in patients undergoing intense insulin treatment.
However, vitreous levels of IGF-I may be more relevant to the initiation of vascular pathology. We examined IGF-I levels in vitreous and demonstrated a threefold increase in levels of IGF-I in diabetics with PDR compared to non-diabetic individuals. 12 This was later confirmed by Meyer-Schwickerath. 13 In vitro studies also established the presence of IGF-IR on human retinal endothelial cells (HRECs) and correlated receptor number with growth rates of cells, with rapidly proliferating cells showing the highest receptor number. 14 These studies support a critical role for IGF-I in normal development, suggesting that serum and tissue levels of IGF-I and IGF-IR surface expression in cells must be carefully regulated for normal development. In contrast, ocular pathologies are associated with dysregulated levels of both IGF-I and IGF-IR. 7 Thus, we sought to target the IGF-IR exclusively in only proliferating endothelial cells within the retinal vasculature. This approach provides a unique antiangiogenic strategy free of toxicity to resident endothelial cells and other nonendothelial cell types in the retina but deleterious only to proliferating endothelial cells.
Results
The ET e /Cdc6 p enhancer/promoter expresses luciferase specifically in cultured endothelial cells Figure 1 shows the expression cassette maps of the plasmids. The proliferating endothelial promoters are composed of either a 4 Â (1297) or a 7 Â (1298) 46-mer multimerized endothelin enhancer (ET e ) upstream of a human Cdc6 promoter (Cdc6 p ). Consensus intron/exon intervening sequence (IVS) 12 and IVS 8 exist for mRNA processing. The IGF-IR ribozyme and hairpin processing ribozyme were cloned into the 3 0 end of the luciferase gene directly after the luciferase stop codon.
The IGF-IR ribozyme and hairpin processing ribozyme have been previously described. 15 The IGF-IR ribozyme is a 34 nt ribozyme consisting of two 6 nt targeting arms and an internal 4 bp stem with a tetra-loop. The hairpin processing ribozyme is cloned 6 bp downstream of the IGF-IR ribozyme. A hairpin cleavage site recognized by the hairpin processing ribozyme is inserted between the IGF-IR ribozyme and the hairpin processing ribozyme. Self-cleavage by the hairpin processing ribozyme at this cleavage site generates a specific 3 0 end for the IGF-IR ribozyme and results in a transcript with five additional nucleotides at the 3 0 end of the IGF-IR ribozyme. This configuration limits the number of nucleotides at the 3 0 end of the IGF-IR ribozyme that could interfere with proper folding of this ribozyme with its target.
HRECs and fibroblasts were transfected with luciferase expression plasmids driven by the proliferating endothelium promoter (ET e /Cdc6 p ). The luciferase assays are shown in Figure 2 and Table 1 and they demonstrate that the 4 Â ET e and the 7 Â ET e promoters yielded 200-fold higher expression of luciferase in the endothelial cells compared with fibroblasts. A 12-fold higher expression of luciferase was observed in endothelial cells compared to fibroblasts transfected with the construct containing the ribozyme. Expression of the constructs containing the IGF-IR hammerhead/hairpin ribozymes was lower than constructs containing the promoter and luciferase alone. This reduction was attributed to loss of the polyA signal as a result of the hairpin ribozyme cleaving its target at the 3 0 end of the IGF-IR ribozyme.
The ET e /Cdc6 p enhancer/promoter expresses luciferase specifically in RECs in vivo
The intravitreal injection of pLUC1298 into the OIR mouse model (Figure 3) or the adult mouse model of laser-induced retinopathy ( Figure 4 ) resulted in expression of luciferase (green) only in the endothelial cells of blood vessels. Staining of retina with rhodamine conjugated to agglutinin identified the retinal vasculature (red). When luciferase is superimposed with the rhodamine, it appears yellow. Immunohistochemical analysis demonstrated that luciferase expression was restricted to the vessels as there was only luciferase surrounding the lumens perfused with rhodaminelabeled dextran. Figure 1 The ET e /Cdc6 p expression cassettes. In the pLUC1297 and pLUC1298 plasmids, the ETe/Cdc6p drives the expression of luciferase and contains a polyA signal. In the pLUC1297HHHP and pLUC1298HHHP plasmids, the ET e /Cdc6 p drives the expression of luciferase and the IGF-IR ribozyme and a hairpin ribozyme that selfcleaves the transcript at the 3 0 end of the IGF-IR ribozyme. These two plasmids contain no polyA signal. The 1297 plasmids contain four ET enhancers and the 1298 plasmids contain seven ET enhancers. Figure 2 The ET e /Cdc6 p limits expression of luciferase to HRECs. Expression of luciferase by pLUC1297 and pLUC1298 in HRECs is approximately 200-fold greater than in human fibroblasts. Expression of luciferase by pLUC1297 and pLUC1298 in HRECs is approximately 12-fold greater than expression of luciferase by pLUC1297HHHP and pLUC1298HHHP in HRECs owing to transcript instability resulting from the lack of a polyA signal. Cell-specific ribozyme expression in mouse retina LC Shaw et al
The ET e /Cdc6 p -driven expression of the IGF-IR ribozyme reduces abnormal pre-retinal neovascularization in the OIR mouse model Figure 5 shows that expression of the IGF-IR ribozyme from pLUC1298HHHP reduces abnormal angiogenesis in the injected eye ( Figure 5a ) compared to the uninjected eye ( Figure 5b ). The density of blood vessels, visualized with rhodamine-agglutinin staining, is reduced in the injected eye (Figure 5a ). ), respectively, when compared to the uninjected eyes. The pGEHHHP1298 plasmid (expressing the IGF-IR ribozyme but not luciferase) reduced pre-retinal neovascularization by 5978% (P ¼ 5.7 Â 10
À28
). As expected, the parent plasmids, pLUC1297 and pLUC1298 not containing the ribozyme constructs, showed no significant difference in the number of pre-retinal nuclei between the injected and uninjected eyes (P ¼ 0.5 and 0.4, respectively).
The ET e /Cdc6 p -driven expression of the IGF-IR ribozyme reduces abnormal pre-retinal neovascularization in the adult model of laser-induced retinopathy Figure 7 shows retinas from adult mice undergoing laser-induced branch vessel occlusion to stimulate neovascularization. The retinas were perfused with 
Discussion
We have previously shown reduction of IGF-IR mRNA and protein expression in HRECs using an IGF-IRspecific ribozyme and that this same ribozyme inhibited pre-retinal neovascularization in the OIR mouse model. 15 A CMV enhancer/chicken b-actin promoter (h, i) Uninjected control eyes visualized with images from both red and green channels (h) and red and blue channels (i).
Figure 6
The ET e /Cdc6 p -driven expression of the IGF-IR ribozyme reduces abnormal pre-retinal neovascularization in the OIR mouse model. Summary of the quantitative analysis of the number of preretinal nuclei per cross-section is shown. The pLUC1297HHHP, pLUC1298HHHP and pGEHHHP1298 plasmids equally reduce pre-retinal neovascularization.
Cell-specific ribozyme expression in mouse retina LC Shaw et al drove the expression of the IGF-IR ribozyme in these studies. This promiscuous enhancer/promoter resulted in ribozyme expression in many cell types and in both quiescent and proliferating cells of the mouse retina. This enhancer/promoter did not restrict expression of the IGF-IR ribozyme to areas of neovascularization only. Because IGF-I and its receptor play a major role in vascular development of both mouse and human eyes, 16 the indiscriminant loss of IGF-IR could result in altered vascular development and propagate the ischemia observed in ROP infants or OIR mice. Therefore, we developed a promoter that would restrict expression to rapidly proliferating endothelium for the purpose of minimizing any adverse impact on normal ocular development.
The ET e /Cdc6 p enhancer/promoter is a composite promoter, which, as described previously, 17 shows selective gene expression in proliferating mouse endothelial cells in vitro. It is composed of a multimerized endothelin enhancer combined with a cell cycle-regulated Cdc6 promoter. Interestingly, ligation of the IGF-IR hammerhead ribozyme and the hairpin ribozyme caused the endothelin enhancers to be deleted in several strains of bacteria, DH5a, Stable 2s and Top Tens. While initially the placement of luciferase was used solely to validate cells expressing the construct, the placement of the hammerhead and hairpin ribozymes at the 3 0 end of luciferase prevented the deletion of the endothelin enhancer. Figure 2 demonstrates strong expression of luciferase from the pLUC1297 and pLUC1298 clones in HRECs and essentially no expression of luciferase in human fibroblasts. Luciferase expression from plasmids expressing the IGF-IR ribozyme (pLUC1297HHHP and pLUC1298HHHP) was lower than with parent plasmids. This would be expected, as these transcripts have no polyA tails. Therefore, it is expected that these transcripts would have a higher turnover rate than transcripts with a polyA tail.
Previously, we showed that the multimerized ET e / Cdc6 p promoter restricted expression to endothelial cells in vitro and in vivo.
17 Figure 2 confirms these in vitro results. However, we wanted to examine expression properties specifically in RECs. Our results support specific expression of the IGF-IR ribozyme in vitro to HRECs and in vivo to retinal endothelium of both mouse models.
Our in vivo studies of luciferase expression from pLUC1298 demonstrate that expression is limited to rapidly proliferating endothelial cells of the retinal vasculature, as typified by the neovascularization observed in the OIR mouse model (Figures 3 and 5 ) and in the adult mouse model of laser-induced retinopathy ( Figure 4) . Coexpression of luciferase and the IGF-IR ribozyme from pLUC1298HHHP showed exclusive expression of luciferase in the rapidly proliferating endothelial cells of the retinal vasculature in the OIR mouse model (Figure 5f, g and i) .
In addition, expression of the IGF-IR ribozyme from this particular plasmid also demonstrated that the IGF-IR ribozyme was able to inhibit the pre-retinal neovascularization produced in the OIR mouse model ( Figure 6 ) without deleteriously influencing the deeper retinal vasculature. Pre-retinal neovascularization was reduced by as much as 54711% after injection of pLUC1298HHHP. This is comparable to levels of inhibition of neovascularization when expression of IGF-IR ribozyme is driven by the CVM enhancer/b-actin promoter (6576%). 15 The IGF-IR ribozyme can inhibit pre-retinal neovascularization produced in the adult model of laser-induced neovascularization. This is apparent from the dramatic reduction in leaky vessels in the ribozyme-treated lasered eye compared to the untreated lasered eye (Figure 7) . Therefore, our in vivo results demonstrate that we can limit expression of the potentially therapeutic ribozyme to pathological proliferating endothelial cells of the retina while not affecting healthy quiescent endothelium.
Another remarkable observation is the duration of expression of the luciferase reporter gene. Systemic administration of plasmid DNA alone by hydrodynamic administration results in initial high levels of expression 24 h after injection, which decrease to 7% of the peak value by day 10. 18, 19 Delivery of plasmid alone in the OIR model and formulated plasmid in the adult laser model demonstrates a duration of expression that exceeds the duration of expression observed in other organs following systemic administration. Luciferase expression and ribozyme activity are observed up to 17 days following administration in the OIR model and up to 21 days in the adult model. These time points represent the required termination of the experiment and thus expression may be even longer. This expression also elicits the biological response of preventing aberrant ocular neovascularization. Cell-specific ribozyme expression in mouse retina LC Shaw et al
Although we specifically targeted the IGF-1 system in this study, other key factors critical to development of retinal neovascularization include VEGF. VEGF binds in a distinct pattern to three structurally related tyrosine kinase receptors. Of these, VEGFR1 and VEGFR2 are considered to be the most important for regulation of neovascularization. VEGFR2 has long been considered the major inducer of angiogenesis. VEGF binding to VEGFR2 stimulates the phosphorylation of a variety of proteins in endothelial cells including phospholipase C-g, PI-3 kinase, Ras GTPase activating protein and the src family of proteins, as well as the generation of nitric oxide. VEGF induces endothelial cell growth by activating the RAF-MEK-ERK pathway. VEGF, similar to IGF-I, mediates endothelial cell survival by activating the PI-3 kinase-Akt pathways. The published clinical trials and FDA approval of the anti-VEGF monoclonal antibody bevacizumab (Avastin, Genentech) for the treatment of colorectal cancer marked a milestone for antiangiogenesis therapy. In addition to colorectal cancer, VEGF inhibitors are being investigated in the treatment of renal cell carcinoma, head and neck carcinoma, lung cancer, breast cancer, prostate cancer and a variety of hematological malignancies. 20 New therapies directed at blocking VEGF receptors are currently being developed. 21 Angiogenic factors such as IGF-1 and VEGF are balanced by antiangiogenic growth factors in the normal eye. An imbalance of these factors induces growth of aberrant new blood vessels. The presence of angiogenic growth factors such as IGF-I and VEGF in the retinas and vitreous of patients with vascular retinopathies is well documented. 5, [22] [23] [24] In addition to proangiogenic factors, it has recently become apparent that a variety of endogenous antiangiogenic factors like pigment epitheliumderived factor (PEDF), endostatin and thrombospondin may contribute to vascular quiescence. PEDF, one of the endogenous antiangiogenic factors found in the eye, was first purified from the conditioned medium of human RPE cells 25 and is a member of the serine protease inhibitor (serpin) family with neuroprotective, neurotrophic 25 and antiangiogenic activities. 26 PEDF has potential as a therapeutic agent for retinal and choroidal diseases and has been extensively tested in animal models [27] [28] [29] and is currently being evaluated in a clinical trial. 30 The counterbalance of VEGF and PEDF is supported by the previous demonstrations that either inhibition of the VEGF system or overexpression of PEDF inhibits neovascularization. 28, 31 Epidemiological and mechanistic evidence link IGF-IR activation and signaling to beyond simply pathological angiogenesis and also to tumor biology. Blocking IGF-IR function in tumor cells may result in therapeutic benefits for patients with cancer. [32] [33] [34] [35] Increased levels of this receptor and its cognate ligands have been observed in a variety of solid human tumors. [36] [37] [38] [39] IGF-IR function is implicated in the hallmarks of cancer -self-sufficiency in growth signals, evasion from apoptosis, tissue invasion and metastasis, as well as angiogenesis. While we used ribozymes in this study, many other approaches have been used to study IGF-IR function including dominantnegative mutants, kinase-defective mutants, antisense oligonucleotides, antisense expression plasmids, IGFbinding proteins, soluble forms of the receptor, antagonistic and/or neutralizing antibodies [40] [41] [42] [43] [44] or small molecule kinase inhibitors. 45, 46 These studies demonstrated that, in a variety of experimental settings, interference with IGF-IR function results in inhibition of cancer cell proliferation, 47 survival, 32 anchorageindependent growth in vitro, 48 inhibition of tumor growth and formation of metastasis in vivo 36, 41, 43, 44, 49 and sensitization of cancer cells to various chemotherapeutic and radiation regimens. 46 Experimental evidence clearly supports pursuit of IGF-IR as a target in oncology. Antagonistic antibodies and small molecular mass kinase inhibitors hold therapeutic promise. Drug discovery approaches to target IGF-IR also include antisense oligonucleotides and recombinant IGF-binding proteins. 50, 51 In summary, we have focused on inhibiting ocular angiogenesis using an IGF-IR ribozyme and proliferating endothelial cell-specific promoters. IGF-I plays a prominent role in ROP and PDR and orchestrates the function of VEGF in the eye. 5, 52 The clinical significance of IGF-I in ocular pathology is appreciated, as serum IGF-I levels in premature infants can predict which infants will develop ROP. Targeted reduction of IGF-IR in rapidly proliferating vasculature rather than in quiescent endothelium will be critical to treatment of ROP infants as well as other disorders where the preservation of quiescent vasculature is essential. Our results demonstrate a proof of concept for using plasmid DNA encoding a ribozyme against IGF-IR in a selective manner for safe treatment of neovascularization associated with diseases such as PDR and ROP.
Materials and methods

Cell culture
Human eyes were obtained from National Disease Research Interchange within 36 h of death (n ¼ 6 donors). HRECs were prepared and maintained as previously described. 53 Cells in passages 3-4 and ascertained positive for acetylated LDL were used for this study. Human skin fibroblasts (FG 152 cell line) were a kind gift of Dr Dietmeir Siemen at the University of Florida.
Expression plasmid construction
pLUC1297 and pLUC1298 were isolated from DH5a Escherichia coli (Qiagen Mega Kit). Plasmids were digested with XbaI (New England Biolabs) at base pair 2036 and XhoI (New England Biolabs) at base pair 2254, which represented proliferating endothelial cell-specific promoters. 17 The proliferating endothelial promoter is composed of a 4 Â (1297) and 7 Â (1298) 46-mer multimerized endothelin enhancer upstream of a human Cdc6 promoter. There is a consensus intron/exon IVS 12 and IVS 8 for mRNA processing. The plasmid pGEHHHP1298 was derived from pLUC1298HHHP by removal of the luciferase reporter gene. Synthetic oligomers for the anti-IGF receptor hammerhead/processing hairpin ribozyme 15 (Midland Scientific, Midland, TX, USA) containing Xba1 and Xho1 complementary overhang sequences were ligated into the digested backbone. StblII cells were transformed with the ligation reaction and selected with kanamycin. DNA from bacterial clones was isolated and analyzed for a unique MnII restriction site. For construction of pLUC1297 HHHP and pLUC1298HHHP, the IGF-IR ribozyme/ hammerhead processing ribozyme was cloned into the Cell-specific ribozyme expression in mouse retina LC Shaw et al 3 0 end of the luciferase gene directly after the luciferase stop codon for both 4 Â and 7 Â multimerized endothelin enhancers with the Cdc6 promoter. A glycerol master cell bank was created, plasmid DNA was isolated (Giga Prep Kit, Qiagen) and sequenced for both the ribozyme insert and the ET e /Cdc6 promoter.
Plasmid formulation for adult mouse eye gene transfer
Plasmid DNA was purified from StblII bacteria (Invitrogen) and condensed with a cationic lipid (Lipid 89 Genzyme Corporation) in 40% ethanol/5% dextrose. The ratio of cationic lipid to plasmid DNA nucleotide was 3:1 (mol/mol). The cationic lipid was mixed with a helper lipid mixture composed of lysophosphatidylcholine:monoacylglycerol:free fatty acid (1:4:2; mol/mol/mol). The lengths of the acyl chain helper lipids were 18:2 and the ratio of cationic lipid to helper lipid mixture was 10:90. Ethanol was removed by dialysis against PBS and the final DNA concentration was 0.5 mg/ml.
Transfection of HRECs with lipofectamine
HRECs grown to confluence on 100 mm plates were transfected with the IGF-IR ribozyme plasmid constructs using Lipofectamine 2000 as described. 54 A 728 ml portion of Opti-MEM I was combined with 52 ml of Lipofectamine 2000 (Invitrogen, Rockville, MD, USA) and allowed to stand at room temperature for 5 min. Then, 780 ml of Opti-MEM I was combined with 13 mg of DNA and allowed to stand at room temperature for 5 min. These two solutions were then combined and complexed for 20 min at room temperature. While the solutions were complexing, the cultures were removed from the incubator and the medium from each Petri dish was aspirated and replaced with fresh medium. These plates were then returned to the incubator until the time of addition of the complexes. After 20 min of complexing, the Opti-MEM I/DNA/Lipofectamine 2000 was added to the cultures at 1560 ml per Petri dish. The culture medium was replaced after 24 h. The cells were harvested after 72 h of incubation for further analysis.
Luciferase assay
HRECs were isolated as previously described and plated onto 100 mm dishes. Human skin fibroblasts (FG 152 cell line) were also plated onto 100 mm dishes. Both cell types were transfected with the plasmids (pLUC1297 and pLUC1298) using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocol. At 72 h post-transfection, the cells were washed twice with PBS (Cellgro) and harvested with 100 ml of luciferase cell culture lysis reagent (Promega) containing protease inhibitor cocktail (Sigma). BCA protein assay was performed (Pierce) on the harvested cells. Luciferase assay system (Promega) was used to measure the luminescence in the samples according to the manufacturer's protocol. The relative luminescence units were read on a luminometer with a 2 s delay followed by a 10 s reading time. The samples were normalized to protein levels.
Animals
All animals were treated in accordance with the ARVO statement for the use of animals in Ophthalmic and Vision Research and with the Guide for the Care and Use of Laboratory Animals. All protocols were approved by the IACUC of the University of Florida. C57BL6/J timed pregnant mice and adult mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). The mice were housed in the University of Florida Health Science Center Animal Resources Facilities.
Intraocular injection into the mouse model of oxygen-induced retinopathy
In the neonatal mouse model of oxygen-induced retinopathy, 7-day-old mice were placed with their nursing dams in a 75% oxygen atmosphere for 5 days. 55 Upon return to normal air, these mice develop retinal neovascularization, with peak development occurring 5 days after their return to normoxia. In this study, the mouse pups received a 0.5 ml intravitreal injection of plasmid (2 mg/ml) OD on postnatal day one (P 1 ). After the fifth day following return to normoxia (P 17 ), the animals were killed and the eyes removed and fixed in 4% paraformaldehyde and embedded in paraffin. Three hundred serial sections (6 mm) were cut sagittally through the cornea parallel to the optic disc. Every thirtieth section was placed on slides and stained with hematoxylineosin. Ten sections from each eye were scored in a masked fashion using light microscopy by counting endothelial cell nuclei extending beyond the inner limiting membrane into the vitreous, as described previously. 55 The efficacy of treatment with each plasmid was then calculated as the percent average nuclei per section in the injected eye versus the uninjected contralateral eye. Selected animals were perfused with 4% paraformaldehyde. For these animals, their retinas were removed for immunohistochemistry.
Adult model of laser-induced retinopathy
In this model, laser photocoagulation of retinal vessels was used to stimulate the angiogenesis within and on the retina as described by Grant et al. 56 Six-to eight-week-old C57BL/6 mice (Jackson Laboratories) were intravitreally injected with 2 ml of AAV-VEGF. Expression of VEGF from this construct stimulates the formation of retinal blood vessels when followed by laser injury. The contralateral eye served as a control. One month following intraocular AAV-VEGF, the mice underwent laser occlusion of large venous vessels in the retina. Briefly, mice were anesthetized with an intraperitoneal injection of ketamine (70 mg/kg body weight) and xylazine (14 mg/kg body weight). An argon green laser system (HGM Corporation, Salt Lake City, UT, USA) was used for retinal vessel photocoagulation with the aid of a 78-diopter lens. The blue-green argon laser (wavelength 488-514 nm) was applied to selected venous sites next to the optic nerve. Venous occlusion was accomplished using laser parameters of 1 s duration, 50 mm spot size and an average of 600 mW intensity with an average of 44 burns per retina. Following laser injury, the lasered eye received a 2 ml injection of plasmid containing the IGF-IR ribozymes. Plasmids were formulated with a cationic lipid formulation to facilitate transfection of the adult mouse endothelium, as the adult mouse eye has low transfection efficiencies with plasmid DNA alone. The pLUC1298HHHP plasmid was compared to the pLUC1298 plasmid with same promoter driving luciferase expression without the ribozyme. The formulated plasmid had a final DNA concentration of 0.3 mg/ml.
Cell-specific ribozyme expression in mouse retina LC Shaw et al Three weeks following laser injury and plasmid injection, each mouse was anesthetized and perfused through the left ventricle with 3 ml of 4% paraformaldehyde. The eyes were enucleated and the retinas removed and flatmounted for histopathological studies.
Histopathological studies
The retinas were incubated overnight at 41C in 1:1000 rhodamine-conjugated agglutinin in 10 mM HEPES, 150 mM NaCl and 0.1% Tween 20 (Buffer F) (pH 7.5). After 24 h, the retinas were washed in 10 mM HEPES and 150 mM NaCl (Buffer B) at 41C, the samples were permeabilized in Buffer F for 24 h at 41C and then washed twice in Buffer B. Incubation in ice-cold methanol followed for 2 h on ice. Thereafter, the retinas were incubated in 0. 
Statistical analysis
Data were analyzed by one-way analysis of variance followed by Bonferroni t-test, with either hyperoxia-or vehicle-treated used as a determinant, as appropriate.
Results are reported as mean7s.e. Po0.05 was considered to be significant.
